Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05926622
Recruiting Observational

Clinical and Radiological Outcomes of Medacta Shoulder System FR

NCT05926622 · tracked via the Priya Life Science France tracker
Sponsor
Medacta International SA
Phase
Observational
Started
2022-03-15
Last updated
2025-09-29

Condition(s) studied

Primary OsteoarthritisSecondary OsteoarthritisRotator Cuff Tear ArthropathyRheumatoid Arthritis ShoulderAvascular NecrosisFractureRevision of Shoulder Arthroplasty

Study summary

This is a post-marketing surveillance on Medacta Shoulder System

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients older than 18 years * Patient with one of the following diagnosis: Primary osteoarthritis Secondary osteoarthritis Cuff tear arthropathy; insufficient rotator cuff Acute fracture (\<21d) Rheumatoid or inflammatory arthritis Avascular necrosis Other posttraumatic condition Revision of shoulder arthroplasty Exclusion Criteria: * Patients with malignant diseases (at the time of surgery) * Patients with proven or suspect infections (at the time of surgery) * Patients with functional deficits other than dysfunction of the shoulder (at the time of surgery) * Patients with known incompatibility or allergy to products materials (at the time of surgery)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinique Générale Annecy Annecy France Recruiting

More Medacta International SA trials in France

Bone Fixation of Mpact Double Mobility Cup Active, not recruiting
The Medacta International AMIStem-P Post-Marketing Surveillance Study Active, not recruiting
Multicenter Mpact DM France Recruiting
GMK-UNI Anatomical UKA: Fixation of Cemented vs Cementless Designs Active, not recruiting
The Medacta GMK SpheriKA Post-Marketing Surveillance Study Recruiting

Other trials for the same condition

Exactech Shoulder Post Market Clinical Follow-up Study Recruiting
Perform Humeral System Study Recruiting
G7 BiSpherical Acetabular Shell PMCF Study Active, not recruiting
PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty Active, not recruiting
AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05926622 on ClinicalTrials.gov ↗ ← All trials in France